| Adenovirus serotype 5 hexon mediates liver gene transfer SN Waddington, JH McVey, D Bhella, AL Parker, K Barker, H Atoda, ... Cell 132 (3), 397-409, 2008 | 700 | 2008 |
| Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity DM Roberts, A Nanda, MJE Havenga, P Abbink, DM Lynch, BA Ewald, ... Nature 441 (7090), 239-243, 2006 | 579 | 2006 |
| Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D P Abbink, AAC Lemckert, BA Ewald, DM Lynch, M Denholtz, S Smits, ... Journal of virology 81 (9), 4654-4663, 2007 | 572 | 2007 |
| Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity R Vogels, D Zuijdgeest, R van Rijnsoever, E Hartkoorn, I Damen, ... Journal of virology 77 (15), 8263-8271, 2003 | 564 | 2003 |
| Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys J Liu, KL O’Brien, DM Lynch, NL Simmons, A La Porte, AM Riggs, ... Nature 457 (7225), 87-91, 2009 | 521 | 2009 |
| Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity DH Barouch, MG Pau, JHHV Custers, W Koudstaal, S Kostense, ... The Journal of Immunology 172 (10), 6290-6297, 2004 | 456 | 2004 |
| Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein SM Sumida, DM Truitt, AAC Lemckert, R Vogels, JHHV Custers, MM Addo, ... The Journal of Immunology 174 (11), 7179-7185, 2005 | 419 | 2005 |
| Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease MJE Havenga, AAC Lemckert, O Ophorst, M Van Meijer, WTV Germeraad, ... Journal of virology 76 (9), 4612-4620, 2002 | 282 | 2002 |
| Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon K Radošević, CW Wieland, A Rodriguez, GJ Weverling, R Mintardjo, ... Infection and immunity 75 (8), 4105-4115, 2007 | 228 | 2007 |
| Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors MC Sprangers, W Lakhai, W Koudstaal, M Verhoeven, BF Koel, R Vogels, ... Journal of clinical microbiology 41 (11), 5046-5052, 2003 | 212 | 2003 |
| Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors SM Sumida, DM Truitt, MG Kishko, JC Arthur, SS Jackson, DA Gorgone, ... Journal of virology 78 (6), 2666-2673, 2004 | 207 | 2004 |
| Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset D Rea, FHE Schagen, RC Hoeben, M Mehtali, MJE Havenga, REM Toes, ... Journal of virology 73 (12), 10245-10253, 1999 | 207 | 1999 |
| Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity AAC Lemckert, SM Sumida, L Holterman, R Vogels, DM Truitt, DM Lynch, ... Journal of virology 79 (15), 9694-9701, 2005 | 202 | 2005 |
| Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector S Kostense, W Koudstaal, M Sprangers, GJ Weverling, G Penders, ... Aids 18 (8), 1213-1216, 2004 | 202 | 2004 |
| Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to … D Rea, MJE Havenga, M van den Assem, RPM Sutmuller, A Lemckert, ... The Journal of Immunology 166 (8), 5236-5244, 2001 | 199 | 2001 |
| Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5 L Holterman, R Vogels, R van der Vlugt, M Sieuwerts, J Grimbergen, ... Journal of virology 78 (23), 13207-13215, 2004 | 186 | 2004 |
| Improved adenovirus vectors for infection of cardiovascular tissues MJE Havenga, AAC Lemckert, JM Grimbergen, R Vogels, LGM Huisman, ... Journal of virology 75 (7), 3335-3342, 2001 | 172 | 2001 |
| Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys J Liu, BA Ewald, DM Lynch, M Denholtz, P Abbink, AAC Lemckert, ... Journal of virology 82 (10), 4844-4852, 2008 | 152 | 2008 |
| Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35 S Kälin, B Amstutz, M Gastaldelli, N Wolfrum, K Boucke, M Havenga, ... Journal of virology 84 (10), 5336-5350, 2010 | 148 | 2010 |
| Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase D Nanda, R Vogels, M Havenga, CJ Avezaat, A Bout, PS Smitt Cancer research 61 (24), 8743-8750, 2001 | 144 | 2001 |
